Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Tim K who wrote (2486)	8/29/1998 9:30:00 AM
From: EZLibra	Read Replies (1) \| Respond to of 3702

I don't think we need two more phases either. The first six patients imaged successfully, showing not only safety but clinical responses. And this on an imaging dose of 3mci all of which went to target (IV dosage equivalent would have been about 90 mci). They don't tell us how the patients (all of whom were considered terminal) have fared with a follow-on therapeutic dose but obviously are all still with us. I had heard that none were expected to survive more than 60 days prior to treatment. A Phase II is dose-limiting in order to establish a 'most tolerated dosage'. TCLN is already doing this by virtue of the algorithym employed to measure the rads according to tumor mass. So maybe all we need to do, treatment-wise, is try this on as many patients as possible - typically a Phase III. Let's face it, folks, with the NIH pump, the 10 day radiolabel, the rad formula and the nature of TNT itself Techniclone probably is 'curing' brain cancer. Give it some time and perhaps the use of the word terminal won't automatically be assiciated with glioblastomas. I can't see any reason why the same treatment regimen will not also be effective on any other highly vascularized solid tumors. I'm expecting a slew of new trials for other cancers to start over the next six months.